A phase 1 trial of AP30663, a KCa2 channel inhibitor in development for conversion of atrial fibrillation
A phase 1 trial of AP30663, a KCa2 channel inhibitor in development for conversion of atrial fibrillation
Christina Yfanti,Birgitte Vestbjerg,14 Authors,A. G. Holst
2023 · DOI: 10.1111/bcp.15973
British Journal of Clinical Pharmacology · 3 Citations
TLDR
The aim of this extension phase 1 study was to test AP30663 at higher single doses compared to the first‐in‐human trial.
Abstract
AP30663 is a novel compound under development for pharmacological conversion of atrial fibrillation by targeting the small conductance Ca2+ activated K+ (KCa2) channel. The aim of this extension phase 1 study was to test AP30663 at higher single doses compared to the first‐in‐human trial.